Haystack Analytics Based out of iit bombay, haystackanalytics is a healthtech company creating clinical genomics products, which enable diagnostic labs and hospitals to offer accurate and personalized diagnostics. Copyright © 2025 haystack analytics all rights reserved. this website uses cookies. we use cookies to analyze website traffic and optimize your website experience. by accepting our use of cookies, your data will be aggregated with all other user data.
Haystackanalytics Leader In Infectious Genomics We at haystack are building state of the art genomics technology for accurate personalized clinical decisions. our innovations make genomics to work for clinicians, hospitals and labs with. Haystackanalytics is a seed company based in mumbai (india), founded in 2018 by gaurav srivastava, anirvan chatterjee and kiran kondabagil. it operates as a provider of genomics technology for personalized clinical decisions. 477 followers, 27 following, 491 posts haystackanalytics (@haystack analytics) on instagram: "global innovator in genomics based diagnostics, bringing the tests to the masses one test at a time". Designed for ctos, vps of engineering, directors of engineering, and engineering managers, haystack delivers critical analytics on cycle time, developer to team productivity, and project health.
Haystackanalytics Leader In Infectious Genomics 477 followers, 27 following, 491 posts haystackanalytics (@haystack analytics) on instagram: "global innovator in genomics based diagnostics, bringing the tests to the masses one test at a time". Designed for ctos, vps of engineering, directors of engineering, and engineering managers, haystack delivers critical analytics on cycle time, developer to team productivity, and project health. Based out of iit bombay, haystackanalytics is a healthtech company creating clinical genomics products, which enable diagnostic labs and hospitals to offer accurate and personalized diagnostics. 1200 pathogens including bacteria and fungi. treat infections, protect patients from harm caused by unnecessary antibiotic use, and combat antibiotic resistance. Tested and validated on >10,000 genomes and >1000 clinical samples. high sensitivity and specificity comparable to molecular methods. test cost less than or comparable to culture testing. " whole genome sequencing is the future gold standard in dst. it is comprehensive, accessible, afforda " read more. Genome wide analysis of multi and extensively drug resistant mycobacterium tuberculosis.
Comments are closed.